FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366494265> ?p ?o ?g. }

• W4366494265 endingPage "114716" @default.
• W4366494265 startingPage "114716" @default.
• W4366494265 abstract "Pancreatic ductal adenocarcinoma (PDAC) exhibits a pronounced extracellular matrix (ECM)-rich response, which is produced by an excessive amount of transforming growth factor β (TGF-β), resulting in tumor progression and metastasis. In addition, TGF-β signaling contributes to rapidly acquired resistance and incomplete response to gemcitabine. Recently, selective inhibitors of the TGF-β signaling pathway have shown promise in PDAC treatment, particularly as an option for augmenting responses to chemotherapy. Here, we investigated the synergistic anticancer effects of a small-molecule TGF-β receptor I kinase inhibitor (vactosertib/EW-7197) in the presence of gemcitabine, and its mechanism of action in pancreatic cancer. Vactosertib sensitized pancreatic cancer cells to gemcitabine by synergistically inhibiting their viability. Importantly, the combination of vactosertib and gemcitabine significantly attenuated the expression of major ECM components, including collagens, fibronectin, and α-SMA, in pancreatic cancer compared with gemcitabine alone. This resulted in potent induction of mitochondrial-mediated apoptosis, gemcitabine-mediated cytotoxicity, and inhibition of tumor ECM by vactosertib. Additionally, the combination decreased metastasis through inhibition of migration and invasion, and exhibited synergistic anti-cancer activity by inhibiting the TGF-β/Smad2 pathway in pancreatic cancer cells. Furthermore, co-treatment significantly suppressed tumor growth in orthotopic models. Therefore, our findings demonstrate that vactosertib synergistically increased the antitumor activity of gemcitabine via inhibition of ECM component production by inhibiting the TGF-β/Smad2 signaling pathway. This suggests that the combination of vactosertib and gemcitabine may be a potential treatment option for patients with pancreatic cancer." @default.
• W4366494265 created "2023-04-22" @default.
• W4366494265 creator A5003772834 @default.
• W4366494265 creator A5004018975 @default.
• W4366494265 creator A5004657642 @default.
• W4366494265 creator A5011999134 @default.
• W4366494265 creator A5018869195 @default.
• W4366494265 creator A5020025516 @default.
• W4366494265 creator A5027745499 @default.
• W4366494265 creator A5041994476 @default.
• W4366494265 creator A5045337799 @default.
• W4366494265 creator A5048880389 @default.
• W4366494265 creator A5049018558 @default.
• W4366494265 creator A5068982543 @default.
• W4366494265 creator A5069411286 @default.
• W4366494265 creator A5086312319 @default.
• W4366494265 creator A5091635911 @default.
• W4366494265 date "2023-06-01" @default.
• W4366494265 modified "2023-10-10" @default.
• W4366494265 title "Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer" @default.
• W4366494265 cites W1971730330 @default.
• W4366494265 cites W1974423029 @default.
• W4366494265 cites W2007040134 @default.
• W4366494265 cites W2019692639 @default.
• W4366494265 cites W2026278392 @default.
• W4366494265 cites W2051190668 @default.
• W4366494265 cites W2056514358 @default.
• W4366494265 cites W2058182256 @default.
• W4366494265 cites W2066616821 @default.
• W4366494265 cites W2074629755 @default.
• W4366494265 cites W2094535521 @default.
• W4366494265 cites W2140662194 @default.
• W4366494265 cites W2156668607 @default.
• W4366494265 cites W2172546656 @default.
• W4366494265 cites W2259993316 @default.
• W4366494265 cites W2302011199 @default.
• W4366494265 cites W2512815522 @default.
• W4366494265 cites W2593516067 @default.
• W4366494265 cites W2613659776 @default.
• W4366494265 cites W2683486796 @default.
• W4366494265 cites W2724558203 @default.
• W4366494265 cites W2739708526 @default.
• W4366494265 cites W2744722724 @default.
• W4366494265 cites W2749365082 @default.
• W4366494265 cites W2787016559 @default.
• W4366494265 cites W2804413587 @default.
• W4366494265 cites W2889990912 @default.
• W4366494265 cites W2893792076 @default.
• W4366494265 cites W2896652675 @default.
• W4366494265 cites W2919986358 @default.
• W4366494265 cites W2999417355 @default.
• W4366494265 cites W3008326983 @default.
• W4366494265 cites W3017305512 @default.
• W4366494265 cites W3018913922 @default.
• W4366494265 cites W3045586358 @default.
• W4366494265 cites W3089796023 @default.
• W4366494265 cites W4200233058 @default.
• W4366494265 cites W4220731955 @default.
• W4366494265 cites W4296043184 @default.
• W4366494265 cites W4303413582 @default.
• W4366494265 doi "https://doi.org/10.1016/j.biopha.2023.114716" @default.
• W4366494265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37086509" @default.
• W4366494265 hasPublicationYear "2023" @default.
• W4366494265 type Work @default.
• W4366494265 citedByCount "0" @default.
• W4366494265 crossrefType "journal-article" @default.
• W4366494265 hasAuthorship W4366494265A5003772834 @default.
• W4366494265 hasAuthorship W4366494265A5004018975 @default.
• W4366494265 hasAuthorship W4366494265A5004657642 @default.
• W4366494265 hasAuthorship W4366494265A5011999134 @default.
• W4366494265 hasAuthorship W4366494265A5018869195 @default.
• W4366494265 hasAuthorship W4366494265A5020025516 @default.
• W4366494265 hasAuthorship W4366494265A5027745499 @default.
• W4366494265 hasAuthorship W4366494265A5041994476 @default.
• W4366494265 hasAuthorship W4366494265A5045337799 @default.
• W4366494265 hasAuthorship W4366494265A5048880389 @default.
• W4366494265 hasAuthorship W4366494265A5049018558 @default.
• W4366494265 hasAuthorship W4366494265A5068982543 @default.
• W4366494265 hasAuthorship W4366494265A5069411286 @default.
• W4366494265 hasAuthorship W4366494265A5086312319 @default.
• W4366494265 hasAuthorship W4366494265A5091635911 @default.
• W4366494265 hasBestOaLocation W43664942651 @default.
• W4366494265 hasConcept C118131993 @default.
• W4366494265 hasConcept C121608353 @default.
• W4366494265 hasConcept C126322002 @default.
• W4366494265 hasConcept C185592680 @default.
• W4366494265 hasConcept C189165786 @default.
• W4366494265 hasConcept C2777996000 @default.
• W4366494265 hasConcept C2779013556 @default.
• W4366494265 hasConcept C2780210213 @default.
• W4366494265 hasConcept C2780258809 @default.
• W4366494265 hasConcept C502942594 @default.
• W4366494265 hasConcept C55493867 @default.
• W4366494265 hasConcept C62478195 @default.
• W4366494265 hasConcept C71924100 @default.
• W4366494265 hasConcept C86492073 @default.
• W4366494265 hasConcept C96232424 @default.
• W4366494265 hasConcept C98274493 @default.

• next